Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways

<h3>Background</h3><p dir="ltr">Recent investigations have reported the benefits of using a tyrosine kinase inhibitor, dasatinib (DA), as well as programmed death-ligand 1 (PD-L1) inhibitors in the management of several solid tumors, including breast cancer. Nevertheless,...

Full description

Saved in:

Bibliographic Details
Main Author:	Hadeel Kheraldine (14231609) (author)
Other Authors:	Ishita Gupta (9203073) (author), Farhan Sachal Cyprian (21633524) (author), Semir Vranic (3353012) (author), Halema F. Al-Farsi (21259523) (author), Maysaloun Merhi (4246147) (author), Said Dermime (79420) (author), Ala-Eddin Al Moustafa (14153205) (author)
Published:	2024
Subjects:	Biomedical and clinical sciences Oncology and carcinogenesis Pharmacology and pharmaceutical sciences Dasatinib PD-1/PD-L1 HER2-positive breast cancer EMT Invasion
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
by: Maha, Al-Asmakh
Published: (2020)

Dasatinib and PD-L1 inhibitors provoke toxicity and inhibit angiogenesis in the embryo
by: Maha Al-Asmakh (614593)
Published: (2021)

Neratinib and metformin: A novel therapeutic approach against HER2-Positive Breast Cancer
by: Kheraldine, Hadeel
Published: (2025)

PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer
by: Reem Saleh (3513056)
Published: (2019)

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression
by: Afsheen Raza (492657)
Published: (2023)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
by: Reem Saleh (3513056)
Published: (2019)

Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4+ T Cells
by: Reem Saleh (3513056)
Published: (2019)

Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways
by: Hadeel, Kheraldine
Published: (2021)

Substantial cell apoptosis provoked by naked PAMAM dendrimers in HER2-positive human breast cancer via JNK and ERK1/ERK2 signalling pathways
by: Hadeel Kheraldine (14231609)
Published: (2021)

Editorial: Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
by: Said Dermime (79420)
Published: (2021)

Dynamic Biomarkers of Response to Anti-Immune Checkpoint Inhibitors in Cancer
by: Said Dermime (79420)
Published: (2021)

Immune checkpoint inhibitors: recent progress and potential biomarkers
by: Pramod Darvin (153341)
Published: (2018)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
by: Remy Thomas (702843)
Published: (2021)

Epigenetic regulation of immunosuppressive tumor-associated macrophages through dysregulated microRNAs
by: Aamir Ahmad (233201)
Published: (2022)

Tracheoesophageal fistula and esophageal perforation in a patient with advanced gastroesophageal junction tumor post ramucirumab treatment. A case report and literature review
by: Ahmed Abdalhadi (14152962)
Published: (2023)

DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer
by: Varun Sasidharan Nair (5396393)
Published: (2018)

Metformin and HER2-positive breast cancer: Mechanisms and therapeutic implications
by: Sara S Bashraheel (17807612)
Published: (2023)

Comparative efficacy and safety of PD-1/PD-L1 inhibitors in triple negative breast cancer: a systematic review and network meta-analysis of randomized controlled trials
by: Ibrahim Elmakaty (14614270)
Published: (2023)

DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer
by: Varun Sasidharan Nair (5396393)
Published: (2018)

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy
by: Nassiba Taib (14557385)
Published: (2023)

Unveiling the effect of shapes and electrolytes on the electrocatalytic ethanol oxidation activity of self-standing Pd nanostructures
by: Adewale K., Ipadeola
Published: (2023)

The role of PAK4 in the immune system and its potential implication in cancer immunotherapy
by: Azza Naїja (17280610)
Published: (2021)

Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity
by: Allan Relecom (14153295)
Published: (2021)

Water-pipe smoking promotes epithelial–mesenchymal transition and invasion of human breast cancer cells via ERK1/ERK2 pathways
by: Khaled W. Sadek (14153196)
Published: (2018)

Unveiling the effect of shapes and electrolytes on the electrocatalytic ethanol oxidation activity of self-standing Pd nanostructures
by: Adewale K. Ipadeola (12699590)
Published: (2023)

Gene Expression and miRNAs Profiling: Function and Regulation in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
by: Rasha M. Sareyeldin (18131371)
Published: (2019)

Unveiling the electrochemical CO oxidation activity on support-free porous PdM (M = Fe, Co, Ni) foam-like nanocrystals over a wide pH range
by: Belal, Salah
Published: (2023)

The effect of novel nitrogen-based chalcone analogs on colorectal cancer cells: Insight into the molecular pathways
by: Arij Fouzat, Hassan
Published: (2024)

Dasatinib versus nilotinib as upfront therapy for treatment naïve chronic myeloid leukemia chronic phase
by: Mohamed A. Yassin (16322749)
Published: (2021)

FIP1L1- platelet-derived growth factor receptor A -positive chronic eosinophilic leukemia showing dramatic response to imatinib
by: Mohammad Abu-Tineh (14829313)
Published: (2021)

Dasatinib‐induced chylothorax: An unusual presentation of a common adverse event—A case report with literature review
by: Theresa Paul (13140759)
Published: (2023)

Unveiling the electrochemical CO oxidation activity on support-free porous PdM (M = Fe, Co, Ni) foam-like nanocrystals over a wide pH range
by: Belal Salah (14150460)
Published: (2023)

Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains
by: Morgan Bérard (12219298)
Published: (2023)

Transition markers in Qatari university students' argumentative writing: A cross-linguistic analysis of L1 Arabic and L2 English
by: Abdelhamid M., Ahmed
Published: (2023)

The effect of novel nitrogen-based chalcone analogs on colorectal cancer cells: Insight into the molecular pathways
by: Arij Fouzat Hassan (21767516)
Published: (2024)

The trans-10, cis-12 isomer of conjugated linoleic acid decreases adiponectin assembly by PPARγ-dependent and PPARγ-independent mechanisms
by: Miller, Jessica R.
Published: (2008)

Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies
by: Fawaz E., Alanazi
Published: (2021)

Epigenetic Regulations of Cancer Stem Cells by the Aryl Hydrocarbon Receptor Pathway
by: Sabah, Akhtar
Published: (2020)

The utility of a deep learning-based approach in Her-2/neu assessment in breast cancer
by: Saidul, Kabir
Published: (2023)

Packed‐Bed Microreactor Under Taylor Flow for MOFs Catalyst Testing Demonstrated on Phenylacetylene Hydrogenation
by: Anchu Ashok (14152020)
Published: (2024)